A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by activating the mother’s body’s defences to generate protective antibodies, which are then passed to the developing baby through the placenta. This maternal immunity offers newborns with instant defence from the point of delivery, precisely when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence indicating that a fortnight’s interval is adequate to shield babies born slightly early. Dr Watson advises pregnant women to have the vaccine at the recommended time, whilst noting that protection can still occur even if given later in the third trimester.
- Nearly 85% coverage when vaccinated 4 weeks before birth
- Antibodies from the mother transferred through the placenta safeguard newborns from birth
- Coverage achievable with two-week gap before early delivery
- Vaccination during the third trimester still offers meaningful infant protection
Compelling evidence from current research
The efficacy of the RSV vaccine administered during pregnancy has been established through a extensive research programme conducted across England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that six-month period, providing strong and reliable evidence of the vaccine’s practical effectiveness. The study’s results have been endorsed by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The scale of this research gives healthcare professionals and expectant parents with confidence in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results paint a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV during the study period, with the vast majority being infants whose mothers had not been given the vaccination. This stark contrast highlights the vaccine’s essential role in reducing the risk of serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research analysed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection rates and hospital admissions. The sizeable sample and comprehensive nature of the data gathering ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or limited subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to establish the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology captured practical outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine functions when given across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and its dangers
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to severe, life-threatening chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during peak seasons.
The infection produces inflammation deep within the lungs and airways, making it extremely challenging for affected infants to feed and breathe effectively. Parents often witness their babies struggling visibly, their chests heaving as they work to get enough air into their weakened respiratory system. Whilst the majority of babies recover with palliative treatment, a small but significant number die from respiratory syncytial virus complications each year, making immunisation programmes a critical public health priority for protecting the youngest and most vulnerable members of society.
- RSV produces inflammation in lungs, resulting in serious respiratory problems in infants
- Nearly 50% of newborns catch the virus during their first few months alive
- Symptoms vary between mild colds to serious chest infections that threaten life needing hospital treatment
- Over 20,000 UK babies need serious hospital treatment for RSV each year
- A small number of infants die from RSV complications annually in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have stressed the significance of pregnant women getting their jab at the best time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that the timing is essential for ensuring newborns receive the most robust immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery provides nearly 85% protection, experts encourage women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to enhance the antibodies passed to their babies through the placenta.
The guidance from health authorities remains clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has provided reassurance to pregnant women that protection remains still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy recognises the realities of pregnancy and childbirth whilst ensuring strong safeguarding for vulnerable newborns during their most critical early months when RSV represents the highest danger of severe infection.
Regional differences in vaccine uptake
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Certain regions have attained higher vaccination coverage among eligible pregnant women, whilst others continue working to increase awareness and access to the jab. These regional differences demonstrate variations in healthcare infrastructure, engagement approaches, and local engagement efforts, though the national data demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts deploying varied communication campaigns to connect with expectant mothers
- Regional disparities in vaccine uptake rates in different parts of England necessitate strategic intervention
- Local healthcare systems adapting programmes to align with local requirements and situations
Real-world impact and parent viewpoints
The vaccine’s outstanding effectiveness translates into concrete gains for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the rollout of this preventative solution, the 80% drop in admissions represents thousands of infants protected against critical disease. Parents no longer face the upsetting situation of seeing their babies gasping for air or labour to feed, symptoms that mark severe RSV infections. The vaccine has fundamentally shifted the landscape of neonatal breathing health, giving expectant mothers a proactive tool to shield their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection resulted in profound brain damage, the vaccine’s availability carries deep personal significance. His mother’s advocacy for the jab highlights the transformative consequences that treatable infection can inflict on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story strikes a chord with parents now offered protection. The knowledge that such serious complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to women in pregnancy navigating their third trimester, changing what was once an unavoidable seasonal threat into a controllable health concern.